Cigna
CI

$353.49

0.46%

Market Cap: $98.8B

About: Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.

Employees: 72,500

Financials Hospital & Medical Service Plans

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

43% more call options, than puts

Call options by funds: $1.14B | Put options by funds: $794M

10% more repeat investments, than reductions

Existing positions increased: 600 | Existing positions reduced: 547

1% less funds holding

Funds holding: 1,624 [Q1] → 1,613 (-11) [Q2]

7% less first-time investments, than exits

New positions opened: 138 | Existing positions closed: 149

1.01% less ownership

Funds ownership: 86.51% [Q1] → 85.5% (-1.01%) [Q2]

13% less capital invested

Capital invested by funds: $91.8B [Q1] → $80.3B (-$11.5B) [Q2]

29% less funds holding in top 10

Funds holding in top 10: 41 [Q1] → 29 (-12) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$400

13%

upside

Avg. target

$408

15%

upside

High target

$438

24%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

JP Morgan Lisa Gill 67% 1-year accuracy 16 / 24 met price target	24%upside $438	Overweight Maintained	21 Aug 2024
Cantor Fitzgerald Sarah James 67% 1-year accuracy 84 / 125 met price target	13%upside $400	Overweight Reiterated	19 Aug 2024
Stephens & Co. Scott Fidel 90% 1-year accuracy 28 / 31 met price target	16%upside $410	Overweight Reiterated	2 Aug 2024
Barclays Andrew Mok 80% 1-year accuracy 35 / 44 met price target	15%upside $405	Overweight Maintained	2 Aug 2024
Cantor Fitzgerald Sarah James 67% 1-year accuracy 84 / 125 met price target	13%upside $400	Overweight Reiterated	10 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about CI published over the past 30 days

24/7 Wall Street

If You Can Buy Only 1 Dividend Stock, Make It One of These 3 Income Stars

Dividends are an investor's best friend. While it is a well-known fact the S&P 500 has returned on average 10.5% annually since its inception in 1957, less known is that dividends account for 85% of the index's cumulative total return.

If You Can Buy Only 1 Dividend Stock, Make It One of These 3 Income Stars

The Cigna Group (CI) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

The Cigna Group (NYSE:CI ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 10:45 AM ET Company Participants David Cordani - Chairman and CEO Conference Call Participants Erin Wright - Morgan Stanely Erin Wright Good morning, everyone. Welcome to the Morgan Stanley Healthcare Conference.

The Cigna Group (CI) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

10 ‘enhanced value' stocks of companies expected to grow quickly through 2026

A narrowly focused screen of value stocks highlights stocks trading cheaply to book value, sales and earnings, but which are also expected to increase sales per share rapidly

10 ‘enhanced value' stocks of companies expected to grow quickly through 2026

Evernorth announces another step forward in lowering drug prices by making a Stelara biosimilar available at $0 out of pocket for patients early next year

Estimated to save individual Accredo patients around $4,000 per year Biosimilar price will be more than 80% lower than Stelara list price Accredo patients benefit from the specialty pharmacy's best-in-class clinical support BLOOMFIELD, Conn. , Sept. 5, 2024 /PRNewswire/ -- Evernorth Health Services announced that it plans to have a Stelara biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy, Accredo, beginning in early 2025.

Evernorth announces another step forward in lowering drug prices by making a Stelara biosimilar available at $0 out of pocket for patients early next year

10 High-Yield A-Rated Blue-Chips For Potentially Scary Times Ahead

The economy is stable but cooling, with the labor market showing signs of slowing down. GDP growth is likely to keep falling, and individual companies could suffer. Long-term investors should focus on companies with strong risk management and adaptability to changing economic conditions, ensuring consistent returns and dividend growth. These 10 companies average an A-credit rating and S&P risk management in the top 0.4% of global companies.

10 High-Yield A-Rated Blue-Chips For Potentially Scary Times Ahead

Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary

JERSEY CITY, N.J. , Aug. 28, 2024 /PRNewswire/ -- Celltrion USA announced today that it has signed an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the pharmacy benefits services business of the Cigna Group's Evernorth and one of the nation's leading health insurers, that will help expand patient access to ZYMFENTRA® (infliximab-dyyb), the first and only U.S. Food and Drug Administration (FDA)-approved subcutaneous infliximab.

Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Cigna said on Monday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Zacks Investment Research

Here's Why Cigna (CI) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Cigna (CI) is a Strong Momentum Stock

The Cigna Group Announces Appearance at the Morgan Stanley 22nd Annual Global Healthcare Conference

BLOOMFIELD, Conn., Aug. 15, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that David Cordani, Chairman and Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, in New York, NY.

The Cigna Group Announces Appearance at the Morgan Stanley 22nd Annual Global Healthcare Conference

The Cigna Group Foundation Launches Grant Program To Improve Veteran Mental Health

Initiative commits $9M over three years, with a first-year focus on housing stability Request for application now open for nonprofits prioritizing veteran mental health with programs and services directly connected to housing and homelessness challenges BLOOMFIELD, Conn. , Aug. 12, 2024 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), announced today a new grant program that will commit $9 million over three years to help improve the mental health and well-being of military veterans, with a first-year focus on housing stability among this specific population.

The Cigna Group Foundation Launches Grant Program To Improve Veteran Mental Health

See News Rankings